The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InImmunic Inc (NASDAQ: IMUX) has successfully secured up to $400 million through a private placement to advance its clinical pipeline. The biotechnology company confirmed that $200 million has already been received, with the remaining balance accessible in a second tranche. These funds are specifically earmarked to complete late-stage trials for vidofludimus calcium, a promising treatment for multiple sclerosis. Beyond clinical milestones, the capital injection will support preparations for a potential commercial launch of the drug. CEO Dr. Daniel Vitt emphasized that this financing provides the necessary runway to reach critical Phase 3 objectives. This significant capital raise reduces financial risk for the company as it approaches pivotal data readouts.